<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="b34d3b22-bb47-428e-941e-3be596a2e9de"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>
      <content styleCode="bold">These highlights do not include all the information needed to use DEFLAZACORT TABLETS safely and effectively. See full prescribing information for DEFLAZACORT TABLETS.</content>
      <br/>
      <content styleCode="bold">DEFLAZACORT tablets, for oral use</content>
      <br/>
      <content styleCode="bold">Initial U.S. Approval: 2017</content>
   </title>
   <effectiveTime value="20240806"/>
   <setId root="fb5350d5-ead1-41f4-8b25-0da0bd7fcffe"/>
   <versionNumber value="1"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="650172430"/>
            <name>Sun Pharmaceutical Industries Limited</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="184769029"/>
                        <name>Ohm Laboratories Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70095-040" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70095-040" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70095-041" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70095-041" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70095-042" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70095-042" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70095-043" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70095-043" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="e98593d2-d33f-49bb-bd0e-746c152567fb"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <title/>
               <text/>
               <effectiveTime value="20250318"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="70095-040" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Deflazacort</name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Deflazacort</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="6" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="KR5YZ6AE4B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DEFLAZACORT</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="KR5YZ6AE4B" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DEFLAZACORT</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O8232NY3SJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STARCH, CORN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="100" unit="1"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="70095-040-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250319"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250319"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA217741" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="white" xsi:type="CE">
                              <originalText>white to off-white</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="6" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">C1</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="70095-041" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Deflazacort</name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Deflazacort</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="18" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="KR5YZ6AE4B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DEFLAZACORT</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="KR5YZ6AE4B" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DEFLAZACORT</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O8232NY3SJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STARCH, CORN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="1"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="70095-041-30" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250319"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250319"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA217741" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="white" xsi:type="CE">
                              <originalText>white to off-white</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="10" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">C2</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="70095-042" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Deflazacort</name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Deflazacort</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="30" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="KR5YZ6AE4B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DEFLAZACORT</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="KR5YZ6AE4B" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DEFLAZACORT</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O8232NY3SJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STARCH, CORN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="1"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="70095-042-30" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250319"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250319"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA217741" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="white" xsi:type="CE">
                              <originalText>white to off-white</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="16" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">C3</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="70095-043" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Deflazacort</name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Deflazacort</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="36" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="KR5YZ6AE4B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DEFLAZACORT</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="KR5YZ6AE4B" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DEFLAZACORT</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O8232NY3SJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STARCH, CORN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="1"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="70095-043-30" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250319"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250319"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA217741" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="white" xsi:type="CE">
                              <originalText>white to off-white</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="18" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">C4</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="L55117f9b-ec35-404c-88d9-3bf25e325e5d">
               <id root="2fc2b962-65f6-4c6f-95e7-21b34b63453b"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <title>
                  <content styleCode="bold">RECENT MAJOR CHANGES</content>
               </title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20250319"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table cellspacing="0" cellpadding="0">
                           <tbody>
                              <tr>
                                 <td valign="top">
                                    <paragraph>Warnings and Precautions</paragraph>
                                 </td>
                                 <td valign="top"/>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>Immunosuppression and Increased Risk of Infection (5.2)</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>6/2024</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph/>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="L718c1c94-84c6-4961-9608-0ec627680fbe">
               <id root="db6a40c5-0431-454c-8cd3-e3a112fa568b"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>
                  <content styleCode="bold">1 INDICATIONS AND USAGE</content>
               </title>
               <text>
                  <paragraph>Deflazacort tablets are indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older.<br/>
                     <content styleCode="italics">Additional pediatric use information is approved for PTC Therapeutics, Inc.'s Emflaza<sup>TM</sup> (deflazacort) tablets. However, due to PTC Therapeutics, Inc.'s marketing exclusivity rights, this drug product is not labeled with that information.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20241213"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Deflazacort tablets are corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older (1)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="L56237963-30ee-42d6-ad6f-a4428bcf9b91">
               <id root="a69c441b-6194-4dd4-911f-7f1c0fc900a6"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>
                  <content styleCode="bold">2 DOSAGE AND ADMINISTRATION</content>
               </title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20240307"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>The recommended once-daily dosage is approximately 0.9 mg/kg/day administered orally (2.2)</item>
                           <item>Discontinue gradually when administered for more than a few days (2.3)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Le0304d51-dd10-4eaa-ab06-9223378012ad">
                     <id root="63edc7d9-fc59-42f3-8290-2743d5c55d10"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.1 Assessments Prior to First Dose of Deflazacort Tablets</content>
                     </title>
                     <text>
                        <paragraph>Administer all immunizations according to immunization guidelines prior to starting deflazacort tablets. Administer live-attenuated or live vaccines at least 4 to 6 weeks prior to starting deflazacort tablets <content styleCode="italics">[see Warnings and Precautions (5.8)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240229"/>
                  </section>
               </component>
               <component>
                  <section ID="L24f9ba10-dd6e-44b4-ad5f-6aa7517e60e8">
                     <id root="6535c602-17a0-403f-8dab-a413d301557f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.2 Dosing Information</content>
                     </title>
                     <text>
                        <paragraph>The recommended oral dosage of deflazacort tablets are approximately 0.9 mg/kg/day once daily. If tablets are used, round up to the nearest possible dose. Any combination of the four deflazacort tablet strengths can be used to achieve this dose.</paragraph>
                     </text>
                     <effectiveTime value="20240229"/>
                  </section>
               </component>
               <component>
                  <section ID="Lebd2a457-dd21-41de-83e0-7b77831f86b9">
                     <id root="6ae1f3c3-3579-4b94-b9bc-4b076a4d656d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.3 Discontinuation</content>
                     </title>
                     <text>
                        <paragraph>Dosage of deflazacort tablets must be decreased gradually if the drug has been administered for more than a few days <content styleCode="italics">[see Warnings and Precautions (5.1)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240229"/>
                  </section>
               </component>
               <component>
                  <section ID="Ldd8b4b53-80e7-46cb-9ce8-816025b209a7">
                     <id root="158a8369-1dff-4a91-b360-48dc6a86bde9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.4 Important Preparation and Administration Instructions</content>
                     </title>
                     <text>
                        <paragraph>Deflazacort tablets can be taken with or without food. Do not administer deflazacort tablets with grapefruit juice <content styleCode="italics">[see Drug Interactions (7.1)]. </content>
                        </paragraph>
                        <paragraph>Deflazacort tablets can be administered whole or crushed and taken immediately after mixing with applesauce.</paragraph>
                     </text>
                     <effectiveTime value="20240229"/>
                  </section>
               </component>
               <component>
                  <section ID="L2e023cd2-1cb0-469e-8b00-2d98d27089ae">
                     <id root="47ddc7df-d63e-410a-9159-baf9f9621645"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.5 Dosage Modification for Use with CYP3A4 Inhibitors and Inducers</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">CYP3A4 Inhibitors</content>
                        </paragraph>
                        <paragraph>Give one third of the recommended dosage when deflazacort tablets are administered with moderate or strong CYP3A4 inhibitors. For example, a 36 mg per day dose would be reduced to a 12 mg per day dose when used with moderate or strong CYP3A4 inhibitors <content styleCode="italics">[see Drug Interactions (7.1) and Clinical Pharmacology (12.3)]. </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">CYP3A4 Inducers</content>
                        </paragraph>
                        <paragraph>Avoid use with moderate or strong CYP3A4 inducers with deflazacort tablets <content styleCode="italics">[see Drug Interactions (7.1) and Clinical Pharmacology (12.3)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240229"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="L64c83434-ce40-46b4-b60c-1af13f70ed8b">
               <id root="1c8b56dc-cf1a-44d7-9741-09d70dbd0db4"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>
                  <content styleCode="bold">3 DOSAGE FORMS AND STRENGTHS</content>
               </title>
               <text>
                  <list listType="unordered">
                     <item>6 mg: White to off-white round tablet with “<content styleCode="bold">C1</content>” debossed on one side</item>
                     <item>18 mg: White to off-white round tablet with “<content styleCode="bold">C2</content>” debossed on one side</item>
                     <item>30 mg: White to off-white oval tablet with “<content styleCode="bold">C3</content>” debossed on one side</item>
                     <item>36 mg: White to off-white oval tablet with “C4” debossed on one side        </item>
                  </list>
               </text>
               <effectiveTime value="20240229"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Tablets: 6 mg, 18 mg, 30 mg, and 36 mg (3)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="L48f740c2-a799-4c08-88c2-30f2c338b5a4">
               <id root="3de34151-e682-414f-99df-8746c926f7d2"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>
                  <content styleCode="bold">4 CONTRAINDICATIONS</content>
               </title>
               <text>
                  <paragraph>Deflazacort tablets are contraindicated in patients with known hypersensitivity to deflazacort or to any of the inactive ingredients. Instances of hypersensitivity, including anaphylaxis, have occurred in patients receiving corticosteroid therapy <content styleCode="italics">[see Warnings and Precautions (5.15) and Adverse Reactions (6.2)]</content>.</paragraph>
               </text>
               <effectiveTime value="20240229"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Hypersensitivity to deflazacort or any of the inactive ingredients in deflazacort tablets (4)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Lc91dbb95-6396-4cbc-b11b-e61050658f97">
               <id root="280a33a2-e5da-4fa7-a66a-07c42595f3d7"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>
                  <content styleCode="bold">5 WARNINGS AND PRECAUTIONS</content>
               </title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20250318"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <content styleCode="italics">Alterations in Endocrine Function</content>: Hypothalamic-pituitary-adrenal axis suppression, Cushing’s syndrome, and hyperglycemia can occur; Monitor patients for these conditions with chronic use of deflazacort (2.3, 5.1)</item>
                           <item>
                              <content styleCode="italics">Immunosuppression and Increased Risk of Infection: </content>Increased risk of new, exacerbation, dissemination, or reactivation of latent infections, which can be severe and at times fatal; Signs and symptoms of infection may be masked (5.2)</item>
                           <item>
                              <content styleCode="italics">Alterations in Cardiovascular/Renal Function: </content>Monitor for elevated blood pressure and sodium, and for decreased potassium levels (5.3)</item>
                           <item>
                              <content styleCode="italics">Gastrointestinal Perforation: </content>Increased risk in patients with certain GI disorders; Signs and symptoms may be masked (5.4)</item>
                           <item>
                              <content styleCode="italics">Behavioral and Mood Disturbances: </content>May include euphoria, insomnia, mood swings, personality changes, severe depression, and psychosis (5.5)</item>
                           <item>
                              <content styleCode="italics">Effects on Bones: </content>Monitor for decreases in bone mineral density with chronic use of deflazacort (5.6)</item>
                           <item>
                              <content styleCode="italics">Ophthalmic Effects</content>: May include cataracts, infections, and glaucoma; Monitor intraocular pressure if deflazacort is continued for more than 6 weeks (5.7)</item>
                           <item>
                              <content styleCode="italics">Vaccination: </content>Do not administer live or live attenuated vaccines to patients receiving immunosuppressive doses of corticosteroids. Administer live-attenuated or live vaccines at least 4 to 6 weeks prior to starting deflazacort (5.8)</item>
                           <item>Serious Skin Rashes: Discontinue at the first sign of rash, unless the rash is clearly not drug related (5.9)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="L53ebad6f-1d57-4760-8a32-1e8d8e661af9">
                     <id root="df3658fc-a6b5-4045-bc63-51fa0ca7005a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.1 Alterations in Endocrine Function</content>
                     </title>
                     <text>
                        <paragraph>Corticosteroids, such as deflazacort, can cause serious and life-threatening alterations in endocrine function, especially with chronic use. Monitor patients receiving deflazacort for Cushing’s syndrome, hyperglycemia, and adrenal insufficiency after deflazacort withdrawal. In addition, patients with hypopituitarism, primary adrenal insufficiency or congenital adrenal hyperplasia, altered thyroid function, or pheochromocytoma may be at increased risk for adverse endocrine events.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Risk of Adrenal Insufficiency Following Corticosteroid Withdrawal</content>
                        </paragraph>
                        <paragraph>Corticosteroids produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, with the potential for the development of secondary adrenal insufficiency after withdrawal of corticosteroid treatment. Acute adrenal insufficiency can occur if corticosteroids are withdrawn abruptly, and can be fatal. The degree and duration of adrenocortical insufficiency produced is variable among patients and depends on the dose, frequency, and duration of corticosteroid therapy. The risk is reduced by gradually tapering the corticosteroid dose when withdrawing treatment. This insufficiency may persist, however, for months after discontinuation of prolonged therapy; therefore, in any situation of stress occurring during that period of discontinuation, corticosteroid therapy should be reinstituted. For patients already taking corticosteroids during times of stress, the dosage may need to be increased.</paragraph>
                        <paragraph>A steroid “withdrawal syndrome”, seemingly unrelated to adrenocortical insufficiency, may also occur following abrupt discontinuance of corticosteroids. This syndrome includes symptoms such as anorexia, nausea, vomiting, lethargy, headache, fever, joint pain, desquamation, myalgia, and/or weight loss. These effects are thought to be due to the sudden change in corticosteroid concentration rather than to low corticosteroid levels.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Cushing’s Syndrome</content>
                        </paragraph>
                        <paragraph>Cushing’s syndrome (hypercortisolism) occurs with prolonged exposure to exogenous corticosteroids, including deflazacort. Symptoms include hypertension, truncal obesity and thinning of the limbs, purple striae, facial rounding, facial plethora, muscle weakness, easy and frequent bruising with thin fragile skin, posterior neck fat deposition, osteopenia, acne, amenorrhea, hirsutism and psychiatric abnormalities.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Hyperglycemia</content>
                        </paragraph>
                        <paragraph>Corticosteroids can increase blood glucose, worsen pre-existing diabetes, predispose those on long-term therapy to diabetes mellitus, and may reduce the effect of anti-diabetic drugs.</paragraph>
                        <paragraph>Monitor blood glucose at regular intervals. For patients with hyperglycemia, anti-diabetic treatment should be initiated or adjusted accordingly.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Considerations for Use in Patients with Altered Thyroid Function</content>
                        </paragraph>
                        <paragraph>Metabolic clearance of corticosteroids is decreased in hypothyroid patients and increased in hyperthyroid patients. Changes in thyroid status of the patient may necessitate a dose adjustment of the corticosteroid. When concomitant administration of corticosteroids and levothyroxine is required, administration of corticosteroid should precede the initiation of levothyroxine therapy to reduce the risk of adrenal crisis.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Pheochromocytoma Crisis</content>
                        </paragraph>
                        <paragraph>There have been reports of pheochromocytoma crisis, which can be fatal, after administration of systemic corticosteroids. In patients with suspected or identified pheochromocytoma, consider the risk of pheochromocytoma crisis prior to administering corticosteroids.</paragraph>
                     </text>
                     <effectiveTime value="20240806"/>
                  </section>
               </component>
               <component>
                  <section ID="L9dbea2ab-4608-4f77-ae85-785fe3fb8e15">
                     <id root="43bff312-fdbf-461c-a37a-c340c2171a18"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.2 Immunosuppression and Increased Risk of Infection</content>
                     </title>
                     <text>
                        <paragraph>Corticosteroids, including deflazacort, suppress the immune system and increase the risk of infection with any pathogen, including viral, bacterial, fungal, protozoan, or helminthic pathogens. Corticosteroids can:</paragraph>
                        <list listType="unordered">
                           <item>Reduce resistance to new infections</item>
                           <item>Exacerbate existing infections</item>
                           <item>Increase the risk of disseminated infections</item>
                           <item>Increase the risk of reactivation or exacerbation of latent infections</item>
                           <item>Mask some signs of infections</item>
                        </list>
                        <paragraph>Corticosteroid-associated infections can be mild but can be severe, and at times fatal. The rate of infectious complications increases with increasing corticosteroid dosages.</paragraph>
                        <paragraph>Monitor for the development of infection and consider deflazacort withdrawal or dosage reduction as needed.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Tuberculosis </content>
                        </paragraph>
                        <paragraph>If deflazacort is used to treat a condition in patients with latent tuberculosis or tuberculin reactivity, reactivation of tuberculosis may occur. Closely monitor such patients for reactivation. During prolonged deflazacort therapy, patients with latent tuberculosis or tuberculin reactivity should receive chemoprophylaxis.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Varicella Zoster and Measles Viral Infections</content>
                        </paragraph>
                        <paragraph>Varicella and measles can have a serious or even fatal course in non-immune patients taking corticosteroids, including deflazacort. In corticosteroid-treated patients who have not had these diseases or are non-immune, particular care should be taken to avoid exposure to varicella and measles.</paragraph>
                        <list listType="unordered">
                           <item>If a deflazacort-treated patient is exposed to varicella, prophylaxis with varicella zoster immunoglobulin may be indicated. If varicella develops, treatment with antiviral agents may be considered.</item>
                           <item>If a deflazacort-treated patient is exposed to measles, prophylaxis with immunoglobulin may be indicated.</item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Hepatitis B Virus Reactivation</content>
                        </paragraph>
                        <paragraph>Hepatitis B virus reactivation can occur in patients who are hepatitis B carriers treated with immunosuppressive dosages of corticosteroids, including deflazacort. Reactivation can also occur infrequently in corticosteroid-treated patients who appear to have resolved hepatitis B infection.</paragraph>
                        <paragraph>Screen patients for hepatitis B infection before initiating immunosuppressive (e.g., prolonged) treatment with deflazacort. For patients who show evidence of hepatitis B infection, recommend consultation with physicians with expertise in managing hepatitis B regarding monitoring and consideration for hepatitis B antiviral therapy.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Fungal Infections</content>
                        </paragraph>
                        <paragraph>Corticosteroids, including deflazacort, may exacerbate systemic fungal infections; therefore, avoid deflazacort use in the presence of such infections unless deflazacort is needed to control drug reactions. For patients on chronic deflazacort  therapy who develop systemic fungal infections, deflazacort withdrawal or dose reduction is recommended.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Amebiasis</content>
                        </paragraph>
                        <paragraph>Corticosteroids, including deflazacort, may activate latent amebiasis. Therefore, it is recommended that latent amebiasis or active amebiasis be ruled out before initiating deflazacort in patient who have spent time in the tropics or patient with unexplained diarrhea.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Strongyloides Infestation</content>
                        </paragraph>
                        <paragraph>Corticosteroids, including deflazacort, should be used with great care in patients with known or suspected Strongyloides (threadworm) infestation. In such patients, corticosteroid- induced immunosuppression may lead to Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe enterocolitis and potentially fatal gram-negative septicemia.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Cerebral Malaria </content>
                        </paragraph>
                        <paragraph>Avoid corticosteroids, including deflazacort, in patients with cerebral malaria.</paragraph>
                     </text>
                     <effectiveTime value="20250318"/>
                  </section>
               </component>
               <component>
                  <section ID="L13c068a8-de2e-4a1e-9fbc-f9062f7c7bee">
                     <id root="50fb0991-56b3-47a2-ab7a-1fc5429243cc"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.3 Alterations in Cardiovascular/Renal Function</content>
                     </title>
                     <text>
                        <paragraph>Corticosteroids, including deflazacort, can cause elevation of blood pressure, salt, and water retention, and increased excretion of potassium and calcium. Monitor blood pressure and assess for signs and symptoms of volume overload. Monitor serum potassium levels.</paragraph>
                        <paragraph>Dietary salt restriction and potassium supplementation may be necessary. Deflazacort should be used with caution in patients with congestive heart failure, hypertension, or renal insufficiency.</paragraph>
                        <paragraph>Literature reports suggest an association between use of corticosteroids and left ventricular free wall rupture after a recent myocardial infarction; therefore, therapy with deflazacort should be used with great caution in these patients.</paragraph>
                     </text>
                     <effectiveTime value="20240229"/>
                  </section>
               </component>
               <component>
                  <section ID="L161a9ad3-4c3f-4628-8b52-9d9158ec374a">
                     <id root="10dff49b-df86-411b-818d-7d8e21e70ed4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.4 Gastrointestinal Perforation</content>
                     </title>
                     <text>
                        <paragraph>There is an increased risk of gastrointestinal perforation during corticosteroid use in patients with certain gastrointestinal disorders such as active or latent peptic ulcers, diverticulitis, fresh intestinal anastomoses, and non-specific ulcerative colitis. Signs of gastrointestinal perforation, such as peritoneal irritation, may be masked in patients receiving corticosteroids.</paragraph>
                        <paragraph>Avoid corticosteroids if there is a probability of impending perforation, abscess, or other pyogenic infections; diverticulitis; fresh intestinal anastomoses; or active or latent peptic ulcer.</paragraph>
                     </text>
                     <effectiveTime value="20240229"/>
                  </section>
               </component>
               <component>
                  <section ID="L90a49dbf-bcf5-4d1a-a60e-5611cc7d5bf4">
                     <id root="ef28adf3-f9e7-4bff-a3f9-b48f5af09cba"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.5 Behavioral and Mood Disturbances</content>
                     </title>
                     <text>
                        <paragraph>Potentially severe psychiatric adverse reactions may occur with systemic corticosteroids, including deflazacort<content styleCode="italics">. </content>Symptoms typically emerge within a few days or weeks of starting treatment and may be dose-related. These reactions may improve after either dose reduction or withdrawal, although pharmacologic treatment may be necessary. Psychiatric adverse reactions usually involve hypomanic or manic symptoms (e.g., euphoria, insomnia, mood swings) during treatment and depressive episodes after discontinuation of treatment. Inform patients or caregivers of the potential for behavioral and mood changes and encourage them to seek medical attention if psychiatric symptoms develop, especially if depressed mood or suicidal ideation is suspected.</paragraph>
                     </text>
                     <effectiveTime value="20240229"/>
                  </section>
               </component>
               <component>
                  <section ID="Ld2d10504-1bf1-4f61-8290-992136b79032">
                     <id root="bd54566a-efa0-45c7-9261-920022429fb1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.6 Effects on Bones</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Decreased Bone Mineral Density</content>
                        </paragraph>
                        <paragraph>Corticosteroids, including deflazacort, decrease bone formation and increase bone resorption both through their effect on calcium regulation (i.e., decreasing absorption and increasing excretion) and inhibition of osteoblast function. This, together with a decrease in the protein matrix of the bone secondary to an increase in protein catabolism and reduced sex hormone production, may lead to inhibition of bone growth in pediatric patients and the development of bone loss at any age. Bone loss can predispose patients to vertebral and long bone fractures. Consider a patient’s risk of osteoporosis before initiating corticosteroid therapy.</paragraph>
                        <paragraph>Monitor bone mineral density in patients on long-term treatment with deflazacort.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Avascular Necrosis</content>
                        </paragraph>
                        <paragraph>Corticosteroids, including deflazacort, may cause avascular necrosis.</paragraph>
                     </text>
                     <effectiveTime value="20240229"/>
                  </section>
               </component>
               <component>
                  <section ID="L59838996-883a-438d-b25f-064f83663c22">
                     <id root="f2432f9a-ea13-4768-bc3a-25c9b04a931b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.7 Ophthalmic Effects</content>
                     </title>
                     <text>
                        <paragraph>Use of corticosteroids, including deflazacort, may produce posterior subcapsular cataracts. Corticosteroids may also cause glaucoma with possible damage to the optic nerves, and may increase the risk of secondary ocular infections caused by bacteria, fungi, or viruses.</paragraph>
                        <paragraph>Corticosteroids are not recommended for patients with active ocular herpes simplex.</paragraph>
                        <paragraph>Intraocular pressure may become elevated in some patients taking corticosteroids. If treatment with deflazacort is continued for more than 6 weeks, monitor intraocular pressure.</paragraph>
                     </text>
                     <effectiveTime value="20240229"/>
                  </section>
               </component>
               <component>
                  <section ID="Lbd05f889-80cc-4978-a567-5a98afb13b7c">
                     <id root="6d76c954-2d10-4beb-acbb-7c5b32a7b266"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.8 Immunizations</content>
                     </title>
                     <text>
                        <paragraph>Administer all immunizations according to immunization guidelines prior to starting deflazacort. Administer live-attenuated or live vaccines at least 4 to 6 weeks prior to starting deflazacort. Patients on deflazacort may receive concurrent vaccinations, except for live-attenuated or live vaccines.</paragraph>
                     </text>
                     <effectiveTime value="20240229"/>
                  </section>
               </component>
               <component>
                  <section ID="L831f0a5d-a465-4529-98ee-252687ab4b41">
                     <id root="c7f4c4f7-642e-4605-8282-debf151d88dd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.9 Serious Skin Rashes</content>
                     </title>
                     <text>
                        <paragraph>Toxic epidermal necrolysis has been reported with the use of deflazacort with symptoms beginning within 8 weeks of starting treatment. Discontinue at the first sign of rash, unless the rash is clearly not drug related.</paragraph>
                     </text>
                     <effectiveTime value="20240229"/>
                  </section>
               </component>
               <component>
                  <section ID="L0b0444b0-ef77-42e0-be2a-96e8f56acc26">
                     <id root="f9565976-7dd2-41b0-87f2-92dca902d6c3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.10 Effects on Growth and Development</content>
                     </title>
                     <text>
                        <paragraph>Long-term use of corticosteroids, including deflazacort, can have negative effects on growth and development in children. </paragraph>
                     </text>
                     <effectiveTime value="20240229"/>
                  </section>
               </component>
               <component>
                  <section ID="Ld0d99a30-660b-4004-b1c7-0c491ca28c3c">
                     <id root="6ef69710-652e-4e18-8f09-77553773acd9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.11 Myopathy</content>
                     </title>
                     <text>
                        <paragraph>Patients receiving corticosteroids, including deflazacort, and concomitant therapy with neuromuscular blocking agents (e.g., pancuronium) or patients with disorders of neuromuscular transmission (e.g., myasthenia gravis) may be at increased risk of developing acute myopathy. This acute myopathy is generalized, may involve ocular and respiratory muscles, and may result in quadriparesis. Elevation of creatine kinase may occur. Clinical improvement or recovery after stopping corticosteroids may require weeks to years.</paragraph>
                     </text>
                     <effectiveTime value="20240229"/>
                  </section>
               </component>
               <component>
                  <section ID="L6b9bf497-5470-41a6-9be6-f4c58f8bc84d">
                     <id root="61a525ab-e209-4e05-ac3d-f65471f36cc4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.12 Kaposi’s Sarcoma</content>
                     </title>
                     <text>
                        <paragraph>Kaposi’s sarcoma has been reported to occur in patients receiving corticosteroid therapy, most often for chronic conditions. Discontinuation of corticosteroids may result in clinical improvement of Kaposi’s sarcoma.</paragraph>
                     </text>
                     <effectiveTime value="20240806"/>
                  </section>
               </component>
               <component>
                  <section ID="L047c2aec-7ab5-44a5-8b4a-a5b2dff03d77">
                     <id root="adb8bdb5-1ec2-4946-a196-e56aefedcd0e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.14 Thromboembolic Events</content>
                     </title>
                     <text>
                        <paragraph>Observational studies have shown an increased risk of thromboembolism (including venous thromboembolism) particularly with higher cumulative doses of corticosteroids. It is unclear if risk differs by daily dose or duration of use. Use deflazacort with caution in patients who have or may be predisposed to thromboembolic disorders.</paragraph>
                     </text>
                     <effectiveTime value="20240229"/>
                  </section>
               </component>
               <component>
                  <section ID="L4eac92e7-5946-48a9-9577-96e1a4ae80fb">
                     <id root="71c44910-878c-49e5-8f7d-408f6de83ccb"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.15 Anaphylaxis</content>
                     </title>
                     <text>
                        <paragraph>Rare instances of anaphylaxis have occurred in patients receiving corticosteroid therapy, including deflazacort.</paragraph>
                     </text>
                     <effectiveTime value="20240229"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Lfc129d15-3f30-4631-b988-f538d96c8e78">
               <id root="4a69f0b7-4837-45b9-a8d4-c93d1e268abd"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>
                  <content styleCode="bold">6 ADVERSE REACTIONS</content>
               </title>
               <text>
                  <paragraph>The following serious adverse reactions are discussed in more detail in other sections:</paragraph>
                  <list listType="unordered">
                     <item>Alterations in Endocrine Function <content styleCode="italics">[see Warnings and Precautions (5.1)] </content>
                     </item>
                     <item>Immunosuppression and Increased Risk of Infection<content styleCode="italics"> [see Warnings and Precautions (5.2)]</content>
                     </item>
                     <item>Alterations in Cardiovascular/Renal Function <content styleCode="italics">[see Warnings and Precautions (5.3)]</content>
                     </item>
                     <item>Gastrointestinal Perforation <content styleCode="italics">[see Warnings and Precautions (5.4)]</content>
                     </item>
                     <item>Behavioral and Mood Disturbances <content styleCode="italics">[see Warnings and Precautions (5.5)]</content>
                     </item>
                     <item>Effects on Bones <content styleCode="italics">[see Warnings and Precautions (5.6)]</content>
                     </item>
                     <item>Ophthalmic Effects <content styleCode="italics">[see Warnings and Precautions (5.7)]</content>
                     </item>
                     <item>Immunizations <content styleCode="italics">[see Warnings and Precautions (5.8)]</content>
                     </item>
                     <item>Serious Skin Rashes <content styleCode="italics">[see Warnings and Precautions (5.9)]</content>
                     </item>
                     <item>Effects on Growth and Development <content styleCode="italics">[see Warnings and Precautions (5.10)]</content>
                     </item>
                     <item>Myopathy <content styleCode="italics">[see Warnings and Precautions (5.11)]</content>
                     </item>
                     <item>Kaposi’s Sarcoma <content styleCode="italics">[see Warnings and Precautions (5.12)]</content>
                     </item>
                     <item>Thromboembolic Events <content styleCode="italics">[see Warnings and Precautions (5.14)]</content>
                     </item>
                     <item>Anaphylaxis <content styleCode="italics">[see Warnings and Precautions (5.15)]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20240308"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse reactions (≥ 10% for deflazacort and greater than placebo) are Cushingoid appearance, weight increased, increased appetite, upper respiratory tract infection, cough, pollakiuria, hirsutism, central obesity, and nasopharyngitis (6.1)</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Sun Pharmaceutical Industries, Inc. at 1-800-818-4555 </content>
                           <content styleCode="bold">or FDA at 1-800-FDA-1088 or</content>
                           <content styleCode="bold"> www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Lcfee1ec2-0b1e-4c08-bedf-3171c7172e2c">
                     <id root="726fd820-fbf7-427e-943f-a3fd959f49f5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">6.1 Clinical Trials Experience</content>
                     </title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>In Study 1 <content styleCode="italics">[see Clinical Studies (14)], </content>the adverse reactions that were associated with deflazacort treatment discontinuation, in decreasing order of frequency, were weight increased, obesity, cataract, and sleep disorder.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Most Common Adverse Reactions in Clinical Studies</content>
                        </paragraph>
                        <paragraph>Table 1 lists the adverse reactions that occurred in ≥ 5% of patients in the 0.9 mg/kg/day deflazacort-treated group and that occurred more frequently than in placebo patients in Study 1, which included patients with DMD between the ages of 5 and 15 years.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 1: </content>
                           <content styleCode="bold">Adverse Reactions that Occurred in ≥ 5% of Deflazacort-Treated Patients and </content>
                           <content styleCode="bold">Occurred More Frequently than in Placebo Patients with DMD (Study 1)</content>
                        </paragraph>
                        <table border="1" cellspacing="0" cellpadding="0">
                           <tbody>
                              <tr>
                                 <td valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Adverse Reaction </content>
                                    </paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Deflazacort </content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">0.9 mg/kg/d</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(N = 51)</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">% at 12 weeks</content>
                                    </paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Placebo </content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(N = 50)</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">% at 12 weeks<sup>1</sup>
                                       </content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>Cushingoid appearance</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>33</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>12</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>Weight increased</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>20</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>6</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>Increased appetite</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>14</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>2</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <paragraph>Upper respiratory tract infection</paragraph>
                                 </td>
                                 <td>
                                    <paragraph>12</paragraph>
                                 </td>
                                 <td>
                                    <paragraph>10</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>Cough</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>12</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>6</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>Pollakiuria</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>12</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>2</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>Nasopharyngitis</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>10</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>6</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>Hirsutism</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>10</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>2</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>Central obesity</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>10</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>4</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>Erythema</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>8</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>6</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>Irritability</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>8</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>4</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>Rhinorrhea</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>8</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>0</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>Abdominal discomfort</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>6</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>2</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <sup>[1]</sup> At 12 weeks placebo patients were re-randomized to receive either deflazacort or an active comparator.</paragraph>
                        <paragraph>
                           <content>Common adverse reactions (≥ 5% of deflazacort-treated patients) that occurred over 52 weeks of exposure to deflazacort 0.9 mg/kg/day in Study 1 and at a higher rate than deflazacort 0.9 mg/kg/day in the 12-week placebo-controlled phase of the trial include Cushingoid appearance (60%), hirsutism (35%), weight increased (28%), erythema (28%), central obesity (25%), abdominal pain/abdominal pain upper (18% combined), pollakiuria (15%), constipation (10%), irritability (10%), abnormal behavior (9%), pyrexia (9%), back pain (7%), rash (7%), contusion (6%), nausea (6%), psychomotor hyperactivity (6%), epistaxis (6%), and skin striae (6%).</content>
                        </paragraph>
                        <paragraph>Study 1 also evaluated a higher dosage of deflazacort (1.2 mg/kg/day). Compared with the 0.9 mg/kg/day dosage, deflazacort 1.2 mg/kg/day over 52 weeks was associated with a higher incidence of certain adverse reactions, including Cushingoid appearance (69%), erythema (49%), hirsutism (37%), headache (34%), weight increased (32%), constipation (15%), abdominal pain upper (14%), skin striae (11%), acne (11%), and abdominal discomfort (8%). As there was no additional benefit with the 1.2 mg/kg/day dose of deflazacort, use of deflazacort 1.2 mg/kg/day is not recommended for the treatment of DMD <content styleCode="italics">[see Dosage and Administration (2.2)]. </content>
                        </paragraph>
                        <paragraph>In an additional clinical study of two years duration with extended follow-up (Study 2), many of the same adverse reactions were observed. In addition, musculoskeletal events associated with long-term steroid use were also observed, including muscle weakness, tendon disorder, and osteopenia.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Less Common Adverse Reactions Observed in Clinical Studies</content>
                        </paragraph>
                        <paragraph>Other adverse reactions (≥ 1% frequency in any deflazacort treatment group and greater than placebo) that were observed during the 12-week placebo-controlled phase of Study 1 are shown below.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Eye Disorders: </content>Lacrimation increased</paragraph>
                        <paragraph>
                           <content styleCode="italics">Gastrointestinal Disorders: </content>Dyspepsia, nausea, gastrointestinal disorder</paragraph>
                        <paragraph>
                           <content styleCode="italics">General Disorders and Administration Site Conditions: </content>Thirst</paragraph>
                        <paragraph>
                           <content styleCode="italics">Infections: </content>Hordeolum, impetigo, influenza, otitis externa, pharyngitis, tooth abscess, urinary tract infection, viral infection</paragraph>
                        <paragraph>
                           <content styleCode="italics">Injury, Poisoning and Procedural Complications: </content>Back injury, contusion, face injury, fibula fracture, greenstick fracture, heat exhaustion</paragraph>
                        <paragraph>
                           <content styleCode="italics">Investigations: </content>Glucose urine present, heart rate irregular</paragraph>
                        <paragraph>
                           <content styleCode="italics">Musculoskeletal and Connective Tissue Disorders: </content>Back pain, muscle spasms, myalgia, neck mass, neck pain, pain in extremity</paragraph>
                        <paragraph>
                           <content styleCode="italics">Nervous System Disorders: </content>Dizziness, psychomotor hyperactivity</paragraph>
                        <paragraph>
                           <content styleCode="italics">Psychiatric Disorders: </content>Affect lability, aggression, depression, emotional disorder, middle insomnia, mood altered, mood swings, sleep disorder</paragraph>
                        <paragraph>
                           <content styleCode="italics">Renal and Urinary Disorders: </content>Chromaturia, dysuria, hypertonic bladder</paragraph>
                        <paragraph>
                           <content styleCode="italics">Reproductive System and Breast Disorders: </content>Testicular pain</paragraph>
                        <paragraph>
                           <content styleCode="italics">Respiratory, Thoracic, and Mediastinal Disorders: </content>Hypoventilation, rhinorrhea </paragraph>
                        <paragraph>
                           <content styleCode="italics">Skin and Subcutaneous Tissue Disorders: </content>Acne, alopecia, dermatitis acneiform </paragraph>
                        <paragraph>
                           <content styleCode="italics">Vascular Disorders: </content>Hot flush</paragraph>
                     </text>
                     <effectiveTime value="20240308"/>
                  </section>
               </component>
               <component>
                  <section ID="L29896d5e-3572-4e8f-ab51-10fd1fd40f79">
                     <id root="99be264f-4a66-46b5-8bad-2a9f95242221"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">6.2 Postmarketing Experience</content>
                     </title>
                     <text>
                        <paragraph>The following adverse reactions have been reported during post-approval use of deflazacort worldwide or during post-approval use of other corticosteroids. These reactions are reported voluntarily from a population of uncertain size; therefore, it is not always possible to estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Blood and Lymphatic System Disorders: </content>Leukocytosis</paragraph>
                        <paragraph>
                           <content styleCode="italics">Cardiac Disorder: </content>Heart failure</paragraph>
                        <paragraph>
                           <content styleCode="italics">Eye Disorders: </content>Chorioretinopathy, corneal or scleral thinning</paragraph>
                        <paragraph>
                           <content styleCode="italics">Gastrointestinal Disorders: </content>Acute pancreatitis (especially in children), hemorrhage, peptic ulceration, perforation of peptic ulcer</paragraph>
                        <paragraph>
                           <content styleCode="italics">General Disorders and Administration Site Conditions: </content>Edema, impaired healing</paragraph>
                        <paragraph>
                           <content styleCode="italics">Immune System Disorders: </content>Hypersensitivity including anaphylaxis</paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism and Nutrition Disorders: </content>Impaired carbohydrate tolerance with increased requirement for anti-diabetic therapy, negative protein and calcium balance, potassium loss and hypokalemic alkalosis when co-administered with beta 2-agonist and xanthines </paragraph>
                        <paragraph>
                           <content styleCode="italics">Musculoskeletal and Connective Tissue Disorders: </content>Avascular necrosis, muscle wasting, negative nitrogen balance, tendonitis and tendon rupture when co-administered with quinolones, vertebral and long bone fractures</paragraph>
                        <paragraph>
                           <content styleCode="italics">Nervous System Disorders: </content>Aggravation of epilepsy, increased intra-cranial pressure with papilledema in children (pseudotumor cerebri) usually after treatment withdrawal, vertigo</paragraph>
                        <paragraph>
                           <content styleCode="italics">Psychiatric Disorders: </content>Anxiety, cognitive dysfunction including confusion and amnesia, delusions, hallucinations, mania, suicidal thoughts</paragraph>
                        <paragraph>
                           <content styleCode="italics">Skin and Subcutaneous Tissue Disorders: </content>Toxic epidermal necrolysis</paragraph>
                        <paragraph>
                           <content styleCode="italics">Vascular Disorders: </content>Thromboembolism, in particular in patients with underlying conditions associated with increased thrombotic tendency, benign intracranial hypertension</paragraph>
                     </text>
                     <effectiveTime value="20240229"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Le89b6c9e-cd01-494a-b73d-9332f0e812b1">
               <id root="8191079d-f8d4-449a-a425-0761f69bb6c1"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>
                  <content styleCode="bold">7 DRUG INTERACTIONS</content>
               </title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20240806"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Moderate or strong CYP3A4 inhibitors: Give one third of the recommended dosage of deflazacort (7.1)</item>
                           <item>Avoid use of moderate or strong CYP3A4 inducers with deflazacort, as they may reduce efficacy (7.1)</item>
                        </list>
                        <paragraph>
                           <content styleCode="italics">Additional pediatric use information is approved for PTC Therapeutics, Inc.'s EmflazaTM (deflazacort) tablets. However, due to PTC Therapeutics, Inc.'s marketing exclusivity rights, this drug product is not labeled with that information.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Lc0526972-4b5f-4b10-8ea5-8459acfba89b">
                     <id root="d4de41b8-810c-48a5-8772-a54690c69498"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">7.1 CYP3A4 Inhibitors and Inducers</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Moderate or Strong CYP3A4 Inhibitors</content>
                        </paragraph>
                        <paragraph>The active metabolite of deflazacort, 21-desDFZ, is a substrate of CYP3A4 <content styleCode="italics">[see Clinical Pharmacology (12.3)]</content>. Co-administration of deflazacort with clarithromycin, a strong CYP3A4 inhibitor, increased total exposure to 21-desDFZ by about 3-fold. Therefore, give one third the recommended dosage of deflazacort when moderate or strong CYP3A4 inhibitors (e.g., clarithromycin, fluconazole, diltiazem, verapamil, grapefruit juice) are used concomitantly with deflazacort <content styleCode="italics">[see Dosage and Administration (2.5) and Clinical Pharmacology (12.3)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Moderate or Strong CYP3A4 Inducers</content>
                        </paragraph>
                        <paragraph>Co-administration of deflazacort with rifampin, a strong CYP3A4 inducer, significantly decreased the exposure of 21-desDFZ. Avoid concomitant use of strong (e.g., efavirenz) or moderate (e.g., carbamazepine, phenytoin) CYP3A4 inducers with deflazacort <content styleCode="italics">[see Dosage and Administration (2.5) and Clinical Pharmacology (12.3)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240307"/>
                  </section>
               </component>
               <component>
                  <section ID="Labd0b6b8-4cf0-4ef8-b4c2-aa7e103c17bb">
                     <id root="ad2dac3e-4156-4590-840e-6786005d07da"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">7.2 Neuromuscular Blockers</content>
                     </title>
                     <text>
                        <paragraph>Patients receiving corticosteroids, including deflazacort, and concomitant therapy with neuromuscular blocking drugs (e.g., pancuronium) may be at increased risk of developing an acute myopathy <content styleCode="italics">[see Warnings and Precautions (5.11)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240229"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="L9f05f106-4839-488d-8537-c92c2fe1dec9">
               <id root="7b93246d-6210-44e0-89b1-0825920c3dcf"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>
                  <content styleCode="bold">8 USE IN SPECIFIC POPULATIONS</content>
               </title>
               <text/>
               <effectiveTime value="20240229"/>
               <component>
                  <section ID="Lb77f44a9-049f-43e6-a297-d47eb6456364">
                     <id root="7ec17872-a3db-411c-aaca-3e5df3f1b59c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">8.1 Pregnancy</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Infants born to mothers who have received substantial doses of corticosteroids during pregnancy should be carefully observed for signs of hypoadrenalism. There are no adequate and well-controlled studies with deflazacort in pregnant women to inform drug-associated risks.</paragraph>
                        <paragraph>Corticosteroids, including deflazacort, readily cross the placenta. Adverse developmental outcomes, including orofacial clefts (cleft lip, with or without cleft palate) and intrauterine growth restriction, and decreased birth weight, have been reported with maternal use of corticosteroids, including deflazacort, during pregnancy. Some epidemiologic studies report an increased risk of orofacial clefts from about 1 per 1,000 infants to 3 to 5 per 1,000 infants; however, a risk for orofacial clefts has not been observed in all studies. Intrauterine growth restriction and decreased birth weight appear to be dose-related; however, the underlying maternal condition may also contribute to these risks <content styleCode="italics">(see Data). </content>The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.</paragraph>
                        <paragraph>Animal reproduction studies have not been conducted with deflazacort. Animal reproduction studies conducted with other corticosteroids in pregnant mice, rats, hamsters, and rabbits using clinically relevant doses have shown an increased incidence of cleft palate. An increase in embryofetal death, intrauterine growth retardation, and constriction of the ductus arteriosus were observed in some animal species.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Human Data </content>
                        </paragraph>
                        <paragraph>Multiple cohort and case-controlled studies in humans suggest that maternal corticosteroid use during the first trimester increases the rate of cleft lip, with or without cleft palate, from about 1/1,000 infants to 3 to 5/1,000 infants. Two prospective case-controlled studies showed decreased birth weight in infants exposed to maternal corticosteroids <content styleCode="italics">in utero</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240229"/>
                  </section>
               </component>
               <component>
                  <section ID="La05e2ee5-79b9-44cf-b962-668d4b5706ff">
                     <id root="673df479-595d-469f-a9e7-6a124c78667c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">8.2 Lactation</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for deflazacort and any potential adverse effects on the breastfed infant from deflazacort. There are no data on the effects on milk production.</paragraph>
                     </text>
                     <effectiveTime value="20240329"/>
                  </section>
               </component>
               <component>
                  <section ID="Lddc334ab-5e5f-4026-98ca-042f043127a7">
                     <id root="3e195ba6-036b-48cf-90e4-592fdb66e4df"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">8.4 Pediatric Use</content>
                     </title>
                     <text>
                        <paragraph>
                           <content>The safety and effectiveness of deflazacort for the treatment of DMD have been established in patients 5 years of age and older. Use of deflazacort in pediatric patients is supported by a multicenter, randomized, double-blind, placebo-and active-controlled study in 196 males 5 to 15 years of age </content>
                           <content styleCode="italics">[see Clinical Studies (14)]</content>
                           <content>.</content>
                        </paragraph>
                        <paragraph>Safety and effectiveness in pediatric patients below the age of 2 years have not been established.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Juvenile Animal Toxicity Data</content>
                        </paragraph>
                        <paragraph>Oral administration of deflazacort (0, 0.1, 0.3, and 1 mg/kg/day) to juvenile rats from postnatal day (PND) 21 to 80 resulted in decreased body weight gain and adverse effects on skeletal development (including decreased cellularity of growth plate and altered bone distribution) and on lymphoid tissue (decreased cellularity). A no-effect dose was not identified. In addition, neurological and neurobehavioral abnormalities were observed at the mid and/or high dose. Plasma 21-desDFZ exposure (AUC) at the lowest dose tested (0.1 mg/kg/day) was lower than that in humans at the recommended human dose of deflazacort (0.9 mg/kg/day).</paragraph>
                        <paragraph>
                           <content styleCode="italics">Additional pediatric use information is approved for PTC Therapeutics, Inc.'s Emflaza<sup>TM</sup> (deflazacort) tablets. However, due to PTC Therapeutics, Inc.'s marketing exclusivity rights, this drug product is not labeled with that information.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240229"/>
                  </section>
               </component>
               <component>
                  <section ID="Ldb28fc32-0b4c-4ef9-b718-43bc58660155">
                     <id root="c8bd776c-27a2-4e77-a36f-97b021b2675f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">8.5 Geriatric Use</content>
                     </title>
                     <text>
                        <paragraph>DMD is largely a disease of children and young adults; therefore, there is no geriatric experience with deflazacort.</paragraph>
                     </text>
                     <effectiveTime value="20240229"/>
                  </section>
               </component>
               <component>
                  <section ID="L3c14a2c0-a843-4c12-9119-cd628e8a2cdf">
                     <id root="4e3f5e02-a739-4cc8-82bf-28302e453252"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">8.6 Renal Impairment</content>
                     </title>
                     <text>
                        <paragraph>No dose adjustment is required in patients with mild, moderate or severe renal impairment <content styleCode="italics">[see Clinical Pharmacology (12.3)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240229"/>
                  </section>
               </component>
               <component>
                  <section ID="La6e4f79e-75ed-4149-a09e-61fc2c38944c">
                     <id root="bad4b6e7-3fb4-4a61-a165-2b02bd403ea0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">8.7 Hepatic Impairment</content>
                     </title>
                     <text>
                        <paragraph>No dose adjustment is required in patients with mild or moderate hepatic impairment <content styleCode="italics">[see Clinical Pharmacology (12.3)]</content>. There is no clinical experience in patients with severe hepatic impairment, and a dosing recommendation cannot be provided for patients with severe hepatic impairment.</paragraph>
                     </text>
                     <effectiveTime value="20240229"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="L4e066089-d8e9-444e-b66d-349d492741cb">
               <id root="a1934ea6-01fd-4433-a391-f40799594228"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>
                  <content styleCode="bold">10 OVERDOSAGE</content>
               </title>
               <text>
                  <paragraph>Treatment of acute overdosage is by immediate gastric lavage or emesis followed by supportive and symptomatic therapy. For chronic overdosage in the face of severe disease requiring continuous steroid therapy, the dosage of deflazacort may be reduced temporarily, or alternate day treatment may be introduced.</paragraph>
               </text>
               <effectiveTime value="20240229"/>
            </section>
         </component>
         <component>
            <section ID="L65a108c4-7697-460c-8448-65e14efb68a7">
               <id root="1b7c7bc6-024c-48da-acd9-aa5b9cf64355"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>
                  <content styleCode="bold">11 DESCRIPTION</content>
               </title>
               <text>
                  <paragraph>The active ingredient in deflazacort tablets is deflazacort (a corticosteroid). Corticosteroids are adrenocortical steroids, both naturally occurring and synthetic. The molecular formula for deflazacort is C<sub>25</sub>H<sub>31</sub>NO<sub>6</sub>. The chemical name for deflazacort is 16α,17-isoxazole-11β,21-dihydroxypregna-1,4-diene-3,20-dione 21acetate, and the structure is:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L3d76983d-b6b0-41ec-adfb-be9a29d231f9"/>
                  </paragraph>
                  <paragraph>Deflazacort is a white or almost white crystalline powder and has a molecular weight of 441.52. Deflazacort is soluble in dichloromethane and chloroform, slightly soluble in ethanol and ethyl acetate, almost insoluble in water.</paragraph>
                  <paragraph>Deflazacort tablets for oral administration are available as an immediate-release tablet in strengths of 6, 18, 30 and 36 mg. Each tablet contains deflazacort and the following inactive ingredients: colloidal silicon dioxide, lactose monohydrate, magnesium stearate, and pregelatinized starch (maize).</paragraph>
               </text>
               <effectiveTime value="20240229"/>
               <component>
                  <observationMedia ID="L3d76983d-b6b0-41ec-adfb-be9a29d231f9">
                     <text>defla-structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="defla-structure.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Lf961101d-dbb5-4a8c-be51-f4bac412b6d7">
               <id root="b679076f-287e-463b-9480-e7b59d276cf4"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>
                  <content styleCode="bold">12 CLINICAL PHARMACOLOGY</content>
               </title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20240229"/>
               <component>
                  <section ID="Lfd0d35ba-28d6-4ddf-ab0b-f77094307025">
                     <id root="3b7bc47c-a68d-4243-9bc5-a7f83f673713"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">12.1 Mechanism of Action</content>
                     </title>
                     <text>
                        <paragraph>Deflazacort is a corticosteroid prodrug, whose active metabolite, 21-desDFZ, acts through the glucocorticoid receptor to exert anti-inflammatory and immunosuppressive effects. The precise mechanism by which deflazacort exerts its therapeutic effects in patients with DMD is unknown.</paragraph>
                     </text>
                     <effectiveTime value="20240229"/>
                  </section>
               </component>
               <component>
                  <section ID="L881ffa0b-5036-4962-8ece-e4ef3fb219fa">
                     <id root="3844fa14-e6ff-4ffb-8bb9-01f9f52717ce"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">12.3 Pharmacokinetics</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Absorption</content>
                        </paragraph>
                        <paragraph>After oral administration in the fasted state, the median T<sub>max </sub>with deflazacort tablets is about 1 hour (range 0.25 to 2 hours).</paragraph>
                        <paragraph>
                           <content styleCode="italics">Food Effect: </content>Co-administration of deflazacort tablets with a high-fat meal reduced C<sub>max </sub>by about 30% and delayed T<sub>max </sub>by one hour, relative to administration under fasting conditions, but there was no effect on the overall systemic absorption as measured by AUC. The bioavailability of deflazacort tablets was similar to that of the oral suspension. The administration of deflazacort with food or crushed in applesauce did not affect the absorption and bioavailability of deflazacort.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                        </paragraph>
                        <paragraph>The protein binding of the active metabolite of deflazacort is about 40%.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Elimination</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism </content>
                        </paragraph>
                        <paragraph>Deflazacort is rapidly converted to the active metabolite 21-desDFZ by esterases after oral administration. 21-desDFZ is further metabolized by CYP3A4 to several other inactive metabolites, including 6β-hydroxy-21-desacetyl deflazacort.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Excretion </content>
                        </paragraph>
                        <paragraph>Urinary excretion is the predominant route of deflazacort elimination (about 68% of the dose), and the elimination is almost completed by 24 hours post dose. 21-desDFZ accounts for 18% of the eliminated drug in the urine.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Specific Populations</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Pediatric Patients </content>
                        </paragraph>
                        <paragraph>The C<sub>max </sub>values (Geometric mean, %CV) of 21-desDFZ in children (ages 4 to 11, N = 16) and adolescents (ages 12 to 16, N = 8) was 206 ng/mL (95.6%) and 381 ng/mL (37.7%), respectively, on Day 1 after administration of 0.9 mg/kg deflazacort. The AUC<sub>inf</sub> (Geometric mean, %CV) of 21-desDFZ in children (ages 4 to 11, N = 16) and adolescents (ages 12 to 16, N = 8) was 400 ng<sub>•</sub>h/mL (87.5%) and 655 ng<sub>•</sub>h/mL (58.1%) on Day 1 after administration of 0.9 mg/kg deflazacort.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Male and Female Patients </content>
                        </paragraph>
                        <paragraph>There are no differences in the pharmacokinetics of 21-desDFZ between males and females.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Racial or Ethnic Groups </content>
                        </paragraph>
                        <paragraph>There are no differences in the pharmacokinetics of 21-desDFZ between Caucasians and non-Caucasians.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Patients with Renal Impairment</content>
                        </paragraph>
                        <paragraph>In a study (N = 16) comparing subjects with end stage renal disease (creatinine clearance less than 15 mL/min) with healthy matched controls, 21-desDFZ exposure was similar between the groups.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Patients with Hepatic Impairment </content>
                        </paragraph>
                        <paragraph>In a study (N = 16) comparing subjects with moderate hepatic impairment (Child-Pugh Class B) with healthy matched controls, 21-desDFZ exposure was similar between the groups. There is no experience in patients with severe hepatic impairment.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Drug Interaction Studies</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">In Vivo Assessment of Drug Interactions </content>
                        </paragraph>
                        <paragraph>Compared to administration of deflazacort alone, administration of deflazacort following multiple doses of a strong CYP3A4 and Pgp inhibitor (clarithromycin) resulted in markedly higher C<sub>max</sub>, AUC<sub>last</sub>, and AUC<sub>inf </sub>values of 21-desDFZ. Geometric mean exposure (C<sub>max</sub>, AUC<sub>last</sub>, and AUC<sub>inf</sub>) of 21-desDFZ ranged from 2.3-fold to 3.4-fold higher following administration of clarithromycin <content styleCode="italics">[see Dosage and Administration (2.5)]</content>.</paragraph>
                        <paragraph>Compared to administration of deflazacort alone, administration of deflazacort following multiple doses of a strong CYP3A4 inducer (rifampicin) resulted in markedly lower C<sub>max</sub>, AUC<sub>last</sub>, and AUC<sub>inf </sub>values of 21-desDFZ. Geometric mean exposures (C<sub>max</sub>, AUC<sub>last</sub>, and AUC<sub>inf</sub>) of 21-desDFZ were approximately 95% lower following administration of rifampin <content styleCode="italics">[see Drug Interactions (7.1)]</content>.</paragraph>
                        <paragraph>6β-Hydroxy-21-desacetyl deflazacort, a secondary and inactive metabolite, is not expected to cause any clinically meaningful interactions with the CYP enzymes or transporters.</paragraph>
                        <paragraph>
                           <content styleCode="italics">In Vitro Assessment of Drug Interactions </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Drug-Metabolizing Enzyme Inhibition</content>
                        </paragraph>
                        <paragraph>21-desDFZ at clinically relevant concentrations did not inhibit CYP1A2, 2C9, 2C19, 3A4, UGT1A1, UGT1A4, UGT1A6, UGT1A9, or UGT2B7 and exhibited weak and not likely clinically meaningful inhibition for 2B6, 2C8, 2D6, and 3A4, UGT1A3 and UGT2B15.</paragraph>
                        <paragraph>6β-Hydroxy-21-desacetyl deflazacort at clinically relevant concentrations did not significantly inhibit CYP2C19, 3A4 1A2, 2B6, 2C8, 2C9, or 2D6.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Drug-Metabolizing Enzyme Induction</content>
                        </paragraph>
                        <paragraph>21-desDFZ and 6β-hydroxy-21-desacetyl deflazacort at clinically relevant concentrations did not significantly induce CYP1A2, 2B6, or 3A4.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Transporters</content>
                        </paragraph>
                        <paragraph>Both deflazacort and 21-desDFZ are substrates of Pgp. 21-desDFZ is not a substrate for BCRP. Neither deflazacort nor 21-desDFZ inhibited Pgp or BCRP <content styleCode="italics">in vitro</content>. 21-desDFZ was not a substrate for SLC transporters OATP1B1 or OATP1B3, and did not inhibit SLC transporters OATP1B1, OATP1B3, OAT1, OAT3, or OCT2.</paragraph>
                        <paragraph>6β-Hydroxy-21-desacetyl deflazacort at clinically relevant concentrations did not significantly inhibit BCRP, OAT1, OAT3, Pgp, OATP1B1, OATP1B3 MATE1, MATE2-K, OCT1, OCT2, or BSEP transporters.</paragraph>
                     </text>
                     <effectiveTime value="20240229"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="L9bf4cee9-2ad1-4a1c-a0ae-4f86fb9604ae">
               <id root="f8c00722-e48a-438d-ae43-aff62bd89a2e"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>
                  <content styleCode="bold">13 NONCLINICAL TOXICOLOGY</content>
               </title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20240229"/>
               <component>
                  <section ID="L75297001-9c51-45ea-8718-a70136bf80d6">
                     <id root="06c40ab5-24cb-4033-9826-0e9effa1b389"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Carcinogenesis</content>
                        </paragraph>
                        <paragraph>In a published 2-year carcinogenicity study in rats, oral administration of deflazacort (0, 0.03, 0.06, 0.12, 0.25, 0.50, or 1 mg/kg/day) resulted in bone tumors (osteosarcoma and osteoma) of the head at 0.25 mg/kg/day, the highest evaluable dose. Doses higher than 0.25 mg/kg/day could not be evaluated for tumors because of a marked decrease in survival.</paragraph>
                        <paragraph>In a 6-month carcinogenicity study in transgenic (Tg.RasH2) mice, oral administration of deflazacort (0, 2, 5, or 20 mg/kg/day in males; 0, 0.5, 2, or 5 mg/kg/day in females) resulted in an increase in stomach tumors (adenoma) at the highest dose tested in males and females. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Mutagenesis</content>
                        </paragraph>
                        <paragraph>Deflazacort and 21-desDFZ were negative in <content styleCode="italics">in vitro </content>(bacterial reverse mutation and human lymphocyte chromosomal aberration) assays and deflazacort was negative in an <content styleCode="italics">in vivo </content>(rat micronucleus) assay.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Impairment of Fertility</content>
                        </paragraph>
                        <paragraph>Fertility studies in animals were not conducted with deflazacort. No effects on the male reproductive system were observed following oral administration of deflazacort to monkeys (0, 1, 3, or 6 mg/kg/day) for 39 weeks or rats (0, 0.05, 0.15, or 0.5 mg/kg/day) for 26 weeks. Plasma 21-desDFZ exposures (AUC) at the highest doses tested in monkey and rat were 4 and 2 times, respectively, that in humans at the recommended human dose of deflazacort (0.9 mg/kg/day).</paragraph>
                     </text>
                     <effectiveTime value="20240229"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="L70798012-71f8-46e3-86b9-d5b6f8ad2bea">
               <id root="c2b5d5cc-ed99-4144-8c88-f744a5126e3e"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>
                  <content styleCode="bold">14 CLINICAL STUDIES</content>
               </title>
               <text>
                  <paragraph>The effectiveness of deflazacort for the treatment of DMD was established in Study 1, a multicenter, randomized, double-blind, placebo-controlled, 52-week study conducted in the US and Canada. The study population consisted of 196 male pediatric patients 5 to 15 years of age with documented mutation of the dystrophin gene, onset of weakness before 5 years of age, and serum creatinine kinase activity at least 10 times the upper limit of normal (ULN) at some stage in their illness. Patients were randomized to therapy with deflazacort (0.9 or 1.2 mg/kg/day), an active comparator, or placebo. A comparison to placebo was made after 12 weeks of treatment. After 12 weeks, placebo patients were re-randomized to receive either deflazacort or the active comparator; all patients continued treatment for an additional 40 weeks. Baseline characteristics were comparable between the treatment arms.</paragraph>
                  <paragraph>In Study 1, efficacy was evaluated by assessing the change between Baseline and Week 12 in average strength of 18 muscle groups. Individual muscle strength was graded using a modified Medical Research Council (MRC) 11-point scale, with higher scores representing greater strength.</paragraph>
                  <paragraph>The change in average muscle strength score between Baseline and Week 12 was significantly greater for the deflazacort 0.9 mg/kg/day dose group than for the placebo group (see Table 2).</paragraph>
                  <paragraph>
                     <content styleCode="bold">Table 2: Analysis of Change from Baseline at Week 12 in Average Muscle Strength Score (Study 1) </content>
                  </paragraph>
                  <table styleCode="TableGrid" width="613px" border="1" cellspacing="0" cellpadding="0">
                     <tbody>
                        <tr>
                           <td valign="top">
                              <paragraph>
                                 <content styleCode="bold">Treatment </content>
                              </paragraph>
                           </td>
                           <td valign="top">
                              <paragraph>
                                 <content styleCode="bold">N</content>
                              </paragraph>
                           </td>
                           <td valign="top">
                              <paragraph>
                                 <content styleCode="bold">Change from Baseline</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">LS Mean (95% CI)</content>
                              </paragraph>
                           </td>
                           <td valign="top">
                              <paragraph>
                                 <content styleCode="bold">P-value</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top">
                              <paragraph>Deflazacort 0.9 mg/kg/day</paragraph>
                           </td>
                           <td valign="top">
                              <paragraph>51</paragraph>
                           </td>
                           <td valign="top">
                              <paragraph>0.15 (0.01, 0.28)</paragraph>
                           </td>
                           <td valign="top">
                              <paragraph>0.017</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top">
                              <paragraph>Placebo</paragraph>
                           </td>
                           <td valign="top">
                              <paragraph>50</paragraph>
                           </td>
                           <td valign="top">
                              <paragraph>-0.10 (-0.23, 0.03)</paragraph>
                           </td>
                           <td valign="top">
                              <paragraph/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content>Compared with the deflazacort 0.9 mg/kg/day group, the deflazacort 1.2 mg/kg/day group demonstrated a small additional benefit compared to placebo at Week 12, but had a greater incidence of adverse reactions. Therefore, use of a 1.2 mg/kg/day dosage of deflazacort is not recommended </content>
                     <content styleCode="italics">[see Dosage and Administration (2.2)]</content>
                     <content>.</content>
                  </paragraph>
                  <paragraph>Although not a pre-specified statistical analysis, compared with placebo, the deflazacort 0.9 mg/kg/day dose group demonstrated at Week 52 the persistence of the treatment effect observed at Week 12 and the small advantage of the 1.2 mg/kg/day dose that was observed at Week 12 was no longer present. Also not statistically controlled for multiple comparisons, results on several timed measures of patient function (i.e., time to stand from supine, time to climb 4 stairs, and time to walk or run 30 feet) numerically favored deflazacort 0.9 mg/kg/day at Week 12, in comparison with placebo.</paragraph>
                  <paragraph>An additional randomized, double-blind, placebo-controlled, 104-week clinical trial evaluated deflazacort in comparison to placebo (Study 2). The study population consisted of 29 male children 6 to 12 years of age with a DMD diagnosis confirmed by the documented presence of abnormal dystrophin or a confirmed mutation of the dystrophin gene. The results of the analysis of the primary endpoint of average muscle strength scores in Study 2 (graded on a 0 to 5 scale) at 2 years were not statistically significant, possibly because of a limited number of patients remaining in the placebo arm (subjects were discontinued from the trial when they lost ambulation). Although not statistically controlled for multiple comparisons, average muscle strength scores at Months 6 and 12, as well as the average time to loss of ambulation, numerically favored deflazacort in comparison with placebo.</paragraph>
               </text>
               <effectiveTime value="20240307"/>
            </section>
         </component>
         <component>
            <section ID="L2b3d0eb9-b611-4603-bac9-8d52381b64c8">
               <id root="8e5ce220-d91d-4134-9ab7-d072c8dd535a"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20240308"/>
               <component>
                  <section ID="L13266749-e7d6-46f1-a2ef-d787b8dddaef">
                     <id root="3f4d9d46-c297-41a7-988d-416245badc87"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">16.1 How Supplied</content>
                     </title>
                     <text>
                        <list listType="unordered">
                           <item>
                              <content styleCode="bold">Deflazacort Tablets, </content>
                              <content styleCode="bold">6 mg</content> are white to off-white round tablet with “<content styleCode="bold">C1</content>” debossed on one side. They are supplied as follows:</item>
                        </list>
                        <paragraph>      NDC 70095-040-01      Bottle of 100 tablets (with child-resistant closure)</paragraph>
                        <list listType="unordered">
                           <item>
                              <content styleCode="bold">Deflazacort Tablets, </content>
                              <content styleCode="bold">18 mg</content> are white to off-white round tablet with “<content styleCode="bold">C2</content>” debossed on one side. They are supplied as follows:</item>
                        </list>
                        <paragraph>      NDC 70095-041-30      Bottle of 30 tablets (with child-resistant closure)</paragraph>
                        <list listType="unordered">
                           <item>
                              <content styleCode="bold">Deflazacort Tablets, </content>
                              <content styleCode="bold">30 mg</content> are white to off-white oval tablet with “<content styleCode="bold">C3</content>” debossed on one side. They are supplied as follows:</item>
                        </list>
                        <paragraph>      NDC 70095-042-30      Bottle of 30 tablets (with child-resistant closure)</paragraph>
                        <list listType="unordered">
                           <item>
                              <content styleCode="bold">Deflazacort Tablets, </content>
                              <content styleCode="bold">36 mg</content> are white to off-white oval tablet with “<content styleCode="bold">C4</content>” debossed on one side. They are supplied as follows:</item>
                        </list>
                        <paragraph>      NDC 70095-043-30      Bottle of 30 tablets (with child-resistant closure)</paragraph>
                     </text>
                     <effectiveTime value="20240308"/>
                  </section>
               </component>
               <component>
                  <section ID="L980db851-7b90-4129-b059-be9856a4078c">
                     <id root="3b4cd299-61a5-4cbb-a741-25c9cf676d71"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">16.2 Storage and Handling</content>
                     </title>
                     <text>
                        <paragraph>Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F). [See USP Controlled Room Temperature].</paragraph>
                     </text>
                     <effectiveTime value="20240308"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="L55c3fbb3-4a86-4b57-bd09-b65d79b8c60d">
               <id root="17717c8a-390c-4fb3-bc1d-dd002b3024f9"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>
                  <content styleCode="bold">17 PATIENT COUNSELING INFORMATION</content>
                  <content styleCode="italics"/>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="underline">Administration</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>Warn patients and/or caregivers to not stop taking deflazacort tablets abruptly or without first checking with their healthcare providers as there may be a need for gradual dose reduction to decrease the risk of adrenal insufficiency <content styleCode="italics">[see Dosage and Administration (2.3) and Warnings and Precautions (5.1)]</content>.</item>
                     <item>Deflazacort tablets may be taken with or without food. Do not take deflazacort tablets with grapefruit juice.</item>
                     <item>Deflazacort tablets may be taken whole or crushed and taken immediately after mixing with applesauce.</item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">Increased Risk of Infection</content>
                  </paragraph>
                  <paragraph>Tell patients and/or caregivers to inform their healthcare provider if the patient has had recent or ongoing infections or if they have recently received a vaccine. Medical advice should be sought immediately if the patient develops fever or other signs of infection. Patients and/or caregivers should be made aware that some infections can potentially be severe and fatal.</paragraph>
                  <paragraph>Warn patients who are on corticosteroids to avoid exposure to chickenpox or measles and to alert their healthcare provider immediately if they are exposed <content styleCode="italics">[see Warnings and Precautions (5.2)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Alterations in Cardiovascular/Renal Function</content>
                  </paragraph>
                  <paragraph>Inform patients and/or caregivers that deflazacort tablets can cause an increase in blood pressure and water retention. If this occurs, dietary salt restriction and potassium supplementation may be needed <content styleCode="italics">[see Warnings and Precautions (5.3)]. </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Behavioral and Mood Disturbances</content>
                  </paragraph>
                  <paragraph>Advise patients and/or caregivers about the potential for severe behavioral and mood changes with deflazacort tablets and encourage them to seek medical attention if psychiatric symptoms develop <content styleCode="italics">[see Warnings and Precautions (5.5)]. </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Decreases in Bone Mineral Density</content>
                  </paragraph>
                  <paragraph>Advise patients and/or caregivers about the risk of osteoporosis with prolonged use of deflazacort tablets, which can predispose the patient to vertebral and long bone fractures <content styleCode="italics">[see Warnings and Precautions (5.6)]. </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Ophthalmic Effects</content>
                  </paragraph>
                  <paragraph>Inform patients and/or caregivers that deflazacort tablets may cause cataracts or glaucoma and advise monitoring if corticosteroid therapy is continued for more than 6 weeks <content styleCode="italics">[see Warnings and Precautions (5.7)]. </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Vaccination</content>
                  </paragraph>
                  <paragraph>Advise patients and/or caregivers to bring immunizations up-to-date according to immunization guidelines prior to starting therapy with deflazacort tablets. Live-attenuated or live vaccines should be administered at least 4 to 6 weeks prior to starting deflazacort tablets. Inform patients and/or caregivers that they may receive concurrent vaccinations with use of deflazacort tablets, except for live-attenuated or live vaccines. <content styleCode="italics">[see Warnings and Precautions (5.8)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Serious Skin Rashes</content>
                  </paragraph>
                  <paragraph>Instruct patients and/or caregivers to seek medical attention at the first sign of a rash <content styleCode="italics">[see Warnings and Precautions (5.9)]. </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Drug Interactions</content>
                  </paragraph>
                  <paragraph>Certain medications can cause an interaction with deflazacort tablets. Advise patients and/or caregivers to inform their healthcare provider of all the medicines the patient is taking, including over-the-counter medicines (such as insulin, aspirin or other NSAIDS), dietary supplements, and herbal products. Inform patients and/or caregivers that alternate therapy, dosage adjustment, and/or special test(s) may be needed during the treatment.</paragraph>
               </text>
               <effectiveTime value="20241213"/>
            </section>
         </component>
         <component>
            <section ID="L381bffdc-b903-405f-9102-184500c925d4">
               <id root="cc684a24-5567-40ac-8ddf-50480d6df925"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <title/>
               <text>
                  <paragraph>Manufactured by:</paragraph>
                  <paragraph>
                     <content styleCode="bold">Ohm Laboratories Inc., </content>
                  </paragraph>
                  <paragraph>New Brunswick, NJ 08901</paragraph>
                  <paragraph>Distributed by:</paragraph>
                  <paragraph>
                     <content styleCode="bold">Sun Pharmaceutical Industries, Inc.</content>
                  </paragraph>
                  <paragraph>Cranbury, NJ 08512</paragraph>
                  <paragraph>August 2024                      FDA-02</paragraph>
                  <paragraph>All trademarks are the property of their respective owners.</paragraph>
                  <paragraph>5254614</paragraph>
               </text>
               <effectiveTime value="20241213"/>
            </section>
         </component>
         <component>
            <section ID="L68abd01b-a024-4728-9b97-2ecee8167a82">
               <id root="0e6c4ea6-3a00-4bea-82c0-35a233ef0ef4"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>
                  <content styleCode="bold">PACKAGE LABEL.PRINCIPAL DISPLAY PANEL-6 MG Bottle Label</content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">NDC 70095-040-01</content>
                     <br/>
                     <content styleCode="bold">Deflazacort Tablets</content>
                     <br/>
                     <content styleCode="bold">6 mg</content>
                  </paragraph>
                  <paragraph>for oral use<br/>
                     <content styleCode="bold">Rx Only</content>
                     <br/>
                     <content styleCode="bold">100 Tablets-Bottle Label</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">SUN PHARMA</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <renderMultiMedia referencedObject="L9ae02dcd-09bd-4df3-9aa9-8178dba6e369"/>
                     </content>
                  </paragraph>
               </text>
               <effectiveTime value="20250319"/>
               <component>
                  <observationMedia ID="L9ae02dcd-09bd-4df3-9aa9-8178dba6e369">
                     <text>6mg-bottle</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="6mg-bottle.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Lc75da355-809b-4baf-93c5-c02ce6313860">
               <id root="f282aa65-a274-4f73-8f38-f68e48e4c4b3"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>
                  <content styleCode="bold">PACKAGE LABEL.PRINCIPAL DISPLAY PANEL-6 MG Carton Label</content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">NDC 70095-040-01</content>
                     <br/>
                     <content styleCode="bold">Deflazacort Tablets</content>
                     <br/>
                     <content styleCode="bold">6 mg</content>
                  </paragraph>
                  <paragraph>for oral use<br/>
                     <content styleCode="bold">Rx Only</content>
                     <br/>
                     <content styleCode="bold">100 Tablets-Carton Label</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">SUN PHARMA</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <renderMultiMedia referencedObject="Le06165a1-09c5-4d94-bea1-149a6e9a4800"/>
                     </content>
                  </paragraph>
               </text>
               <effectiveTime value="20250319"/>
               <component>
                  <observationMedia ID="Le06165a1-09c5-4d94-bea1-149a6e9a4800">
                     <text>6mg-carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="6mg-carton.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="L4c989de7-7bd3-4a3b-8ba7-2d44074427ad">
               <id root="43d0ee54-d6fb-403f-8990-cbbf7369df88"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>
                  <content styleCode="bold">PACKAGE LABEL.PRINCIPAL DISPLAY PANEL-18 MG Bottle Label</content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">NDC 70095-041-30</content>
                     <br/>
                     <content styleCode="bold">Deflazacort Tablets</content>
                     <br/>
                     <content styleCode="bold">18 mg</content>
                  </paragraph>
                  <paragraph>for oral use<br/>
                     <content styleCode="bold">Rx Only</content>
                     <br/>
                     <content styleCode="bold">30 Tablets-Bottle Label</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">SUN PHARMA</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <renderMultiMedia referencedObject="Lcf8784e0-2b6c-4ff0-9c48-d54a1b7048f3"/>
                     </content>
                  </paragraph>
               </text>
               <effectiveTime value="20250319"/>
               <component>
                  <observationMedia ID="Lcf8784e0-2b6c-4ff0-9c48-d54a1b7048f3">
                     <text>18mg-bottle</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="18mg-bottle.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Ldab7e981-abb1-44e7-9757-33417eb60f8d">
               <id root="1006be04-980f-41e9-b06a-95c391b96a4b"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>
                  <content styleCode="bold">PACKAGE LABEL.PRINCIPAL DISPLAY PANEL-18 MG Carton Label</content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">NDC 70095-041-30</content>
                     <br/>
                     <content styleCode="bold">Deflazacort Tablets</content>
                     <br/>
                     <content styleCode="bold">18 mg</content>
                  </paragraph>
                  <paragraph>for oral use<br/>
                     <content styleCode="bold">Rx Only</content>
                     <br/>
                     <content styleCode="bold">30 Tablets-Carton Label</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">SUN PHARMA</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <renderMultiMedia referencedObject="Lb156b659-955c-4cbc-b0fe-c8bc867ac51f"/>
                     </content>
                  </paragraph>
               </text>
               <effectiveTime value="20250319"/>
               <component>
                  <observationMedia ID="Lb156b659-955c-4cbc-b0fe-c8bc867ac51f">
                     <text>18mg-carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="18mg-carton.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="L951f73aa-5e78-4437-af50-428760d959cc">
               <id root="c6674818-ae2d-40c6-be0f-710e8dfaa307"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>
                  <content styleCode="bold">PACKAGE LABEL.PRINCIPAL DISPLAY PANEL-30 MG Bottle Label</content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">NDC 70095-042-30</content>
                     <br/>
                     <content styleCode="bold">Deflazacort Tablets</content>
                     <br/>
                     <content styleCode="bold">30 mg</content>
                  </paragraph>
                  <paragraph>for oral use<br/>
                     <content styleCode="bold">Rx Only</content>
                     <br/>
                     <content styleCode="bold">30 Tablets-Bottle Label</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">SUN PHARMA</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <renderMultiMedia referencedObject="L74992e93-5004-4749-a75a-3d197f64ac7e"/>
                     </content>
                  </paragraph>
               </text>
               <effectiveTime value="20250319"/>
               <component>
                  <observationMedia ID="L74992e93-5004-4749-a75a-3d197f64ac7e">
                     <text>30mg-bottle</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="30mg-bottle.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="L4b3786ac-8c31-4f0f-b106-49fceb2ad3bf">
               <id root="6adbe387-cde3-4a98-9c96-fd1bca13b4fc"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>
                  <content styleCode="bold">PACKAGE LABEL.PRINCIPAL DISPLAY PANEL-30 MG Carton Label</content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">NDC 70095-042-30</content>
                     <br/>
                     <content styleCode="bold">Deflazacort Tablets</content>
                     <br/>
                     <content styleCode="bold">30 mg</content>
                  </paragraph>
                  <paragraph>for oral use<br/>
                     <content styleCode="bold">Rx Only</content>
                     <br/>
                     <content styleCode="bold">30 Tablets-Carton Label</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">SUN PHARMA</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <renderMultiMedia referencedObject="L0860de09-964c-450c-9777-431a99005828"/>
                     </content>
                  </paragraph>
               </text>
               <effectiveTime value="20250319"/>
               <component>
                  <observationMedia ID="L0860de09-964c-450c-9777-431a99005828">
                     <text>30mg-carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="30mg-carton.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Lb188aeb0-d1dc-4fc5-bd12-ce7959fea333">
               <id root="2704e5fc-f3f2-423d-bedf-afd84d8e70bc"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>
                  <content styleCode="bold">PACKAGE LABEL.PRINCIPAL DISPLAY PANEL-36 MG Bottle Label</content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">NDC 70095-043-30</content>
                     <br/>
                     <content styleCode="bold">Deflazacort Tablets</content>
                     <br/>
                     <content styleCode="bold">36 mg</content>
                  </paragraph>
                  <paragraph>for oral use<br/>
                     <content styleCode="bold">Rx Only</content>
                     <br/>
                     <content styleCode="bold">30 Tablets-Bottle Label</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">SUN PHARMA</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <renderMultiMedia referencedObject="L5b7b77ea-9957-4f44-9af0-a62c8787a519"/>
                     </content>
                  </paragraph>
               </text>
               <effectiveTime value="20250319"/>
               <component>
                  <observationMedia ID="L5b7b77ea-9957-4f44-9af0-a62c8787a519">
                     <text>36mg-bottle</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="36mg-bottle.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Lf1e3a463-0940-40a1-8810-0ae961e62162">
               <id root="c47260a8-ada3-42d4-a6e9-22cfbcb8d3c5"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>
                  <content styleCode="bold">PACKAGE LABEL.PRINCIPAL DISPLAY PANEL-36 MG Carton Label</content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">NDC 70095-043-30</content>
                     <br/>
                     <content styleCode="bold">Deflazacort Tablets</content>
                     <br/>
                     <content styleCode="bold">36 mg</content>
                  </paragraph>
                  <paragraph>for oral use<br/>
                     <content styleCode="bold">Rx Only</content>
                     <br/>
                     <content styleCode="bold">30 Tablets-Carton Label</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">SUN PHARMA</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <renderMultiMedia referencedObject="Lea822ffb-1095-4412-9345-9d77f7bbc3b0"/>
                     </content>
                  </paragraph>
               </text>
               <effectiveTime value="20250319"/>
               <component>
                  <observationMedia ID="Lea822ffb-1095-4412-9345-9d77f7bbc3b0">
                     <text>36mg-carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="36mg-carton.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>